Current status of therapy of solid tumors: brain tumor therapy.

Journal Article (Review)

Treatment of malignant brain tumors with conventional approaches is largely unsuccessful because curative doses generally cannot be delivered without excessive toxicity to normal brain. Radioimmunotherapy is emerging as an attractive alternative for glioma therapy because of the potential for more selectively irradiating tumor cells while sparing normal tissues. Several institutions are engaged in phase I and phase II trials investigating the therapeutic potential of monoclonal antibodies (mAbs) labeled with the beta-emitters (131)I and (90)Y and the alpha-emitter (211)At in patients with recurrent and newly diagnosed brain tumors. The current status of these trials will be discussed with regard to efficacy, toxicity, and future directions.

Full Text

Duke Authors

Cited Authors

  • Zalutsky, MR

Published Date

  • January 2005

Published In

Volume / Issue

  • 46 Suppl 1 /

Start / End Page

  • 151S - 156S

PubMed ID

  • 15653663

International Standard Serial Number (ISSN)

  • 0161-5505

Language

  • eng

Conference Location

  • United States